Abstract

Alemtuzumab Maintains Efficacy on Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, Over 9 Years in RRMS Patients: CARE-MS II Follow-up (TOPAZ Study) (151)

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call